October 11, 2023

• Two-way borrowing will allow providers to administer state supplied COVID-19 vaccine and nirsevimab to fully insured children and adults or to administer privately purchased COVID-19 vaccine and nirsevimab to VFC eligible children and uninsured or underinsured adults in the event there is a delay in shipment of either stock.
• The purpose of this policy is to prevent missed COVID-19 vaccine and nirsevimab administration opportunities for both VFC/AVP-eligible and fully insured patients.
• The amount of COVID-19 vaccine and nirsevimab that can be borrowed is not limited to a certain amount, however, as with other VFC/AVP vaccine products, the borrowing policy does not alleviate a provider’s responsibility to appropriately order, in a timely manner, enough private COVID-19 vaccine and nirsevimab to vaccinate insured patients within the practice.
  
• The bidirectional COVID-19 vaccine and nirsevimab borrowing policy may not be used as a replacement system for a provider’s privately purchased vaccine inventory.
• Providers must ensure borrowing state supplied COVID-19 vaccine and nirsevimab to immunize a fully insured patient does not prevent an eligible patient from receiving a needed COVID-19 vaccine and nirsevimab.
• Providers agree to follow all VFC/AVP requirements, which include screening patients for eligibility at each immunization encounter and documenting their eligibility status.